POLYMERIC MICELLAR CONTRAST AGENTS FOR CT ANGIOGRAPHY

Information

  • Research Project
  • 6140872
  • ApplicationId
    6140872
  • Core Project Number
    R43HL065052
  • Full Project Number
    1R43HL065052-01
  • Serial Number
    65052
  • FOA Number
  • Sub Project Id
  • Project Start Date
    6/1/2000 - 24 years ago
  • Project End Date
    5/30/2001 - 23 years ago
  • Program Officer Name
    LINDER, BARBARA
  • Budget Start Date
    6/1/2000 - 24 years ago
  • Budget End Date
    5/30/2001 - 23 years ago
  • Fiscal Year
    2000
  • Support Year
    1
  • Suffix
  • Award Notice Date
    5/29/2000 - 24 years ago

POLYMERIC MICELLAR CONTRAST AGENTS FOR CT ANGIOGRAPHY

We intend to develop a new technology for producing efficient contrast imaging agents for x-ray computed tomography (CT) angiography capable of being administered by intravenous injection. These agents consist of amphiphilic biocompatible polymers, able to form submicron particles (micelles) in aqueous solutions. The hydrophobic x-ray dense iodine- containing blocks form the core of the particle, which is surrounded with hydrophilic polymer chains protecting the core from interaction with opsonizing plasma proteins and providing longer circulation times than currently available vascular contrast agents. Use of polymeric micelles as a diagnostic media would result in an improvement in the detection and characterization of lesions located in several different organs including the vasculature system. We plan to reduce both the iodine load to the patient and the time necessary to perform the examination by modifying surface properties of the micelle vesicles. This eventually will lead to the development of a new generation of contrast agents which will be safer for the patient (fewer side effects), more convenient for the radiologist, less expensive to produce, and therefore, more cost-effective. PROPOSED COMMERCIAL APPLICATIONS: Long-circulating micellar agents as contrast media for x-ray CT is potentially useful for diagnostic applications such as ischemic diseases (myocardial or cerebral perfusion defects), vascular diseases and diagnostic or follow-up of endothelial permeability disorders (diabetic patients, tumors, etc.). Identification of a contrast agent that has reduced health risks compared to current radio-opaque drugs and which allows for noninvasive, sensitive, delineation of the vascular system constitutes a significant diagnostic and commercial opportunity.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    98742
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:98742\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    BIOSTREAM THERAPEUTICS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    CAMBRIDGE
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02142
  • Organization District
    UNITED STATES